✦ LIBER ✦

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET

✍ Scribed by Scheffler, Matthias; Kobe, Carsten; Zander, Thomas; Nogova, Lucia; Kahraman, Deniz; Thomas, Roman; Neumaier, Bernd; Dietlein, Markus; Wolf, Jürgen

Book ID: 119320924
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 510 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.110

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

18F-FDG uptake and EGFR mutations in pat

18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis

✍ Na, Im Il; Byun, Byung Hyun; Kim, Kyeong Min; Cheon, Gi Jeong; Choe, Du Hwan; Ko 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 194 KB

A novel EGFR nonsense mutation in a non-

A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib

✍ Ramón González Manzano; Elena Martínez Navarro; Elena Eugenieva; Francisco José 📂 Article 📅 2008 🏛 Springer Milan 🌐 Spanish ⚖ 276 KB

Simultaneous positron emission tomograph

Simultaneous positron emission tomography (PET) assessment of metabolism with 18F-fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine (FLT), and hypoxia with 18fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): A pilot study

✍ Pierre Vera; Pierre Bohn; Agathe Edet-Sanson; Alice Salles; Sebastien Hapdey; Is 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 544 KB